Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Evaluation, Diagnosis and Management of Malignant Processes Affecting the Female...
share announcement

Evaluation, Diagnosis and Management of Malignant Processes Affecting the Female Genitals

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 4140

Special Issue Editors

Prof. Dr. Marius L. Craina

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, University of Medicine and Pharmacy "Victor Babes", 300001 Timisoara, Romania
Interests: gynecology; obstetrics; gynecological oncology; endocrinology and reproductive medicine; ethics; medical education; research design; epidemiology and statistics
Special Issues, Collections and Topics in MDPI journals
Dr. Elena Bernad

E-Mail Website
Co-Guest Editor
Department of Obstetrics and Gynecology, University of Medicine and Pharmacy "Victor Babes", 300001 Timisoara, Romania
Interests: gynecology; obstetrics; gynecological oncology; endocrinology and reproductive medicine; ethics; medical education; research design; epidemiology and statistics; computer applications
Special Issues, Collections and Topics in MDPI journals
Dr. Sandor Bernad

E-Mail Website
Co-Guest Editor
Romanian Academy – Timisoara Branch, Center for Fundamental and Advanced Technical Research, 130004 Timisoara, Romania
Interests: computational fluid mechanics; hemodynamics; cancer vascularization; pathological vascularization of the female genitals; drug targeting; nanoparticle accumulation; ex vivo flow model; therapy; placenta vascularization; fetoplacental circulation

Special Issue Information

Dear Colleagues,

Genital malignancy is currently one of the leading causes of death in women. Prevention and early detection through the application of organized screening programs can substantially contribute to reducing cancer morbidity and mortality. The purpose of this Special Issue is to improve the long-term prognosis of patients and to increase the quality of life of both patients with genital neoplasm and their survivors, families, and caregivers. The continuous development of science in cancer has led to the discovery and implementation of new innovative therapies. In particular, accurate investigations of various physical phenomena occurring in human systems through experimental, theoretical, and computational biomechanics tools are recognized as essential technologies to realize personalized medicine. Additionally, drug targeting draws attention to different therapies’ applications, thanks to their functions to guide and control their interaction with specific target molecules, cells, and tissues. Through this Special Issue, we invite practitioners to share their experiences with the medical world, which could ultimately lead to a collection of information that would improve the approach and treatment of patients. Original research manuscripts, short communications of preliminary but significant results, reviews, and case reports that could contribute to the achievement of the purpose are welcome.

Prof. Dr. Marius L. Craina
Dr. Elena Bernad
Dr. Sandor Bernad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genital neoplasm
  • breast neoplasm
  • diagnosis
  • surgery
  • drug therapy
  • drug targeting
  • computational biomechanics
  • litigation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1751 KiB  
Article
Evaluation of the Safety and Efficacy of Ormeloxifene, a Selective Estrogen Receptor Modulator and Medroxyprogesterone Acetate in Women with Non-Structural Abnormal Uterine Bleeding: A Randomized Clinical Trial
by Suhail Ahmad Mir, Rifat Ara, Fiza Amin, Anjum Malik, Laraibah Hamid, Tabasum Ali, Ghulam Nabi Bader, Shahid Ud Din Wani, Mansour Almuqbil, Sultan Alshehri, Abdulhakeem M. Alshehri and Faiyaz Shakeel
Medicina 2022, 58(11), 1503; https://doi.org/10.3390/medicina58111503 - 22 Oct 2022
Cited by 1 | Viewed by 3420
Abstract
Background and objectives: Abnormal uterine bleeding is a significant clinical and gynaecological concern that necessitates its safe and effective treatment. The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medroxyprogesterone acetate in women [...] Read more.
Background and objectives: Abnormal uterine bleeding is a significant clinical and gynaecological concern that necessitates its safe and effective treatment. The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding. Materials and Methods: A prospective, randomized, single-blinded clinical trial of 367 patients was carried out at a tertiary care hospital for a period of one year from 5 January 2019 to 4 January 2020. Patients were randomized into two groups for administering ormeloxifene and medroxyprogesterone acetate for a 3-month treatment duration and were evaluated by laboratorial investigations like anaemic status, bleeding duration, endometrial thickness, pictorial blood loss assessment chart (PBLAC) score, and patient’s medical and medication history. Health-related quality of life was assessed using short form survey-36 (SF-36) questionnaire scale. Cost-effectiveness was determined on the basis of the three-month treatment regimen. Results: The mean duration of bleeding reduced from 16.88 ± 6.46 to 7.76 ± 1.55 in the ormeloxifene group and from 15.91 ± 5.04 to 8.7 ± 1.91 (p < 0.001) in the medroxyprogesterone acetate. Similarly, mean haemoglobin increased from 8.56 ± 0.77 to 10.1 ± 0.087 g/dL and from 8.60 ±0.97 to 9.551 ± 0.90 g/dL (p < 0.001), and endometrial thickness showed a reduction from 8.52 ± 1.61 mm to 6.92 ± 1.68 mm and from 8.40 ± 2.09 mm to 7.85 ± 2.0 mm (p < 0.001) in the ormeloxifene and medroxyprogesterone acetate groups, respectively. PBLAC score reduced from 289.92 ± 42.39 to 128.11 ± 33.10 and from 287.38 ± 40.94 to 123.5 ± 29.57 (p < 0.001) in these groups, respectively. Health-related quality of life improved in the ormeloxifene group more than the medroxyprogesterone group, which was evidenced by SF-36 scale parameters (physical function, energy/fatigue and pain) that changed from 24.39, 12.99, 6.25 to 28.95, 18, 9 and from 25.41, 13.6, 7.1 to 27.02, 16, 8.3 in the ormeloxifene and medroxyprogesterone acetate groups, respectively. Conclusions: The study concludes that both medroxyprogesterone acetate and ormeloxifene are safe and efficacious in controlling abnormal uterine bleeding, but ormeloxifene was the better of the two in terms of cost effectiveness, reduction in pictorial blood loss assessment score, endometrial thickness, bleeding duration (days), increase in haemoglobin concentration (g/dL) and improvement in the quality of life. Full article
(This article belongs to the Special Issue Evaluation, Diagnosis and Management of Malignant Processes Affecting the Female Genitals)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop